Plasmid DNA Contract Manufacturing Market Size & Share Report, 2033
The global plasmid DNA contract manufacturing market size was estimated at USD 319.16 million in 2023 and is projected to hit around USD 1,879.54 million by 2033, growing at a CAGR of 19.4% during the forecast period from 2024 to 2033.
Key Takeaways:
Plasmid DNA Contract Manufacturing Market Growth
The rapidly growing field of cell and gene therapy is creating overwhelming enthusiasm across the plasmid DNA contract manufacturing market. The increasing usage of gene therapy and mostly CAR-Ts has significantly boosted the demand for plasmid DNA, thus simultaneously supporting its contract manufacturing services. Additionally, technological advancements to overcome the challenges of conventional methods for vector production are anticipated to support the growth of this plasmid DNA contract manufacturing market.
The COVID-19 restrictions fully halted research-based operations and interrupted the healthcare industry. However, the plasmid DNA contract manufacturing market witnessed positive growth in 2020 and 2021. The high growth of the market during the COVID-19 pandemic is due to the increasing research-based activities pertaining to the treatment of the SARS-CoV-2 infection. Several companies initiated the process of research and development of plasmid DNA-based vaccines as a treatment option for COVID-19. For instance, in July 2021, Zydus Cadila announced an application for Emergency Use Authorization for its three-dose Plasmid DNA ZyCoV-D Vaccine against COVID-19.
An increasing number of companies expanding their capacities in the production of plasmid DNA is one of the major factors augmenting the growth of the plasmid DNA contract manufacturing market. For instance, in December 2020, Thermo Fisher Scientific announced the expansion of a new plasmid DNA manufacturing facility in California, with an aim to scale up its cell and gene therapy offerings across plasmid DNA therapeutics. The company cited increasing worldwide demand for vital mRNA-based vaccines and plasmid DNA therapies as the driver for the investment.
Plasmid DNA Contract Manufacturing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 381.08 million |
| Market Size by 2033 | USD 1,879.54 million |
| Growth Rate From 2024 to 2033 | CAGR of 19.4% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Application, therapeutic area, end-user, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Charles River Laboratories, VGXI, Inc.; PlasmidFactory GmbH & Co. KG; Boehringer Ingelheim; BioCina; TriLink Biotechnologies; Aster PTE. LTD; Thermo Fisher Scientific, Inc.; VIVE biotech; Lonza |
Segments Insights:
Application Insights
The plasmid DNA contract manufacturing market is broadly classified into cell & gene therapy, immunotherapy, and others on the basis of application. The cell & gene therapy segment held the leading market share at 62.3% in 2023 and is further anticipated to dominate the market during the forecast period. High shares of the segment are attributable to the increasing number of contract developers expanding their services to include cell & gene-based plasmid DNA manufacturing services. For instance, in October 2022, Ray Therapeutics, along with Forge Biologics, a CDMO, extended their collaboration agreement for the manufacturing of clinical-stage plasmid DNA with an aim to support Ray Therapeutics’ lead optogenetics gene therapy program.
The immunotherapy segment of the plasmid DNA contract manufacturing market is anticipated to witness a stable growth rate of 19.5% across the forecast period. The high growth of the segment is majorly due to the increasing research and development activities pertaining to immunotherapy. Increasing demand for oncology immunotherapy is another significant factor boosting the segment’s growth. The rising number of cancer cases has led to the growth in the development of a larger number of oncology-based immunotherapy products, thus supporting the segment’s growth in the plasmid DNA contract manufacturing market.
End-user Insights
Based on the end-user, the plasmid DNA contract manufacturing market is classified into pharmaceutical and biotechnology companies and research institutes. The pharmaceutical and biotechnology companies segment held the lion’s share of 61.2% in 2023. High shares of the segment are majorly due to the increasing pipeline for plasmid DNA-based therapeutics across the globe. Moreover, an increasing number of pharma and biopharma companies outsourcing their plasmid DNA manufacturing services to contract manufacturers is another primary factor boosting the growth of the plasmid DNA contract manufacturing market. For instance, in February 2022, a survey conducted by Industry Standard Research (ISR), stated that in the survey almost around 46% of respondents indicated they will outsource their Plasmid DNA manufacturing capabilities to contract developers and this is significantly going to increase by 50% in the next five years.
The research institutes segment on the other hand is anticipated to witness a stable growth rate of 19.1% across the forecast period owing to increasing funding for cell & gene therapy-based research. Research institutes are significantly focusing on the R&D of cell & gene therapies due to the growing demand for the same. Hence, the increasing funding coupled with the growing demand for plasmid DNA-based therapeutics will strongly propel the segment’s growth in the plasmid DNA contract manufacturing market.
Therapeutic Area Insights
Based on therapeutic areas, the plasmid DNA contract manufacturing market is classified into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and others. The cancer segment dominated the plasmid DNA contract manufacturing market with a revenue share of 41% in 2023. The high growth of the segment is majorly due to the increasing pipeline and current therapeutics of plasmid DNA in the field of oncology. Moreover, the increasing prevalence rate of cancer cases across the globe is another considerable factor supporting the research-based activities of plasmid DNA for oncology.
The infectious diseases segment on the other hand is anticipated to witness a lucrative growth rate of 19.6% across the forecast period in the plasmid DNA contract manufacturing market. Significant growth of the segment is majorly due to the increasing product commercialization of plasmid DNA therapeutics in the treatment of infectious diseases. For instance, in April 2020, INOVIO and Richter-Helm BioLogics GmbH & Co. KG announced a partnership agreement to expand its manufacturing capabilities to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, for COVID-19 infection.
Regional Insights
Based on regional insights, North America dominated the plasmid DNA contract manufacturing market in 2023 with a revenue share of 50.19%. High shares of the segment are primarily due to the increasing rate of outsourcing activities pertaining to cell & gene therapies across the region and especially in the U.S. For instance, a survey conducted by BioPlan’s 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production stated that approximately 25% of the respondents showed a strong likelihood of outsourcing their production capacities to the U.S. Moreover, an increasing number of contract developers penetrating the U.S. plasmid DNA contract manufacturing market is another significant factor supporting the region’s growth.
On the other hand, Asia Pacific is anticipated to witness a lucrative growth rate of 19.9% across the analysis timeframe. The high growth of the region is primarily due to the increasing rate of outsourcing activities happening across the region. This is attributable to the fact that the region is less expensive in terms of labor and wage charges which attracts a large number of companies to outsource their production capabilities in the region, especially in countries such as India and China.
Some prominent players in the global plasmid DNA contract manufacturing market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Plasmid DNA Contract Manufacturing market.
By Application
By Therapeutic Area
By End-user
By Region
Chapter 1. Plasmid DNA Contract Manufacturing Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. Therapeutic Area
1.1.3. End - user
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. nova one advisor. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Plasmid DNA Contract Manufacturing Market: Executive Summary
2.1. Market Outlook
Chapter 3. Plasmid DNA Contract Manufacturing Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing disease prevalence
3.2.1.2. Growing Investments in Research Studies
3.2.1.3. Growing Popularity of Gene Therapy
3.2.2. Market restraint analysis
3.2.2.1. Lack of advanced infrastructure for manufacturing in certain developing countries
3.2.2.2. Quality Issues associated with Contract Manufacturing
3.2.3. Covid - 19 Impact & Recovery Analysis
3.2.4. Heat Map Analysis
3.2.5. Major Deals and Strategic Alliances Analysis
3.2.6. Industry Analysis - Porter’s
3.2.7. PESTLE Analysis
Chapter 4. Plasmid DNA Contract Manufacturing Market: Application Segment Analysis
4.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
4.2. Plasmid DNA Contract Manufacturing Market: Application Market Share Analysis, 2022 & 2030
4.2.1. Gene Therapy
4.2.1.1. Gene Therapy Market, 2021 - 2033
4.2.2. Immunotherapy
4.2.2.1. Immunotherapy Market, 2021 - 2033
4.2.3. Others
4.2.3.1. Others Market, 2021 - 2033
Chapter 5. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Segment Analysis
5.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
5.2. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2022 & 2030
5.2.1. Cancer
5.2.1.1. Cancer Market, 2021 - 2033
5.2.2. Infectious Diseases
5.2.2.1. Infectious Diseases Market, 2021 - 2033
5.2.3. Autoimmune Diseases
5.2.3.1. Autoimmune Diseases Market, 2021 - 2033
5.2.4. Cardiovascular Diseases
5.2.4.1. Cardiovascular Diseases Market, 2021 - 2033
5.2.5. Others
5.2.5.1. Others Market, 2021 - 2033
Chapter 6. Plasmid DNA Contract Manufacturing Market: End - user Segment Analysis
6.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
6.2. Plasmid DNA Contract Manufacturing Market: End - user Market Share Analysis, 2022 & 2030
6.2.1. Pharmaceutical and Biotechnology Companies
6.2.1.1. Pharmaceutical and Biotechnology Companies Market, 2021 - 2033
6.2.2. Research Institutes
6.2.2.1. Research Institutes Market, 2021 - 2033
Chapter 7. Plasmid DNA Contract Manufacturing Market: Regional Analysis
7.1. Plasmid DNA Contract Manufacturing Market: Regional market share analysis, 2022 & 2030
7.2. North America
7.2.1. North America Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.2.2. U.S.
7.2.2.1. U.S. Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.2.3. Canada
7.2.3.1. Canada Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3. Europe
7.3.1. Europe Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.2. U.K.
7.3.2.1. U.K. Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.3. Germany
7.3.3.1. Germany Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.4. Italy
7.3.4.1. Italy Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.5. Spain
7.3.5.1. Spain Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.6. Denmark
7.3.6.1. Denmark Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.7. Sweden
7.3.7.1. Sweden Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.8. Norway
7.3.8.1. Norway Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.3.9. Rest of EU
7.3.9.1. Rest of EU Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4. Asia Pacific
7.4.1. Asia Pacific Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.2. China
7.4.2.1. China Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.3. India
7.4.3.1. India Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.4. Japan
7.4.4.1. Japan Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.5. Australia
7.4.5.1. Australia Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.6. Thailand
7.4.6.1. Thailand Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.7. South Korea
7.4.7.1. South Korea Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.4.8. Rest of APAC
7.4.8.1. Rest of APAC Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.5. Latin America
7.5.1. Latin America Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.5.2. Brazil
7.5.2.1. Brazil Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.5.3. Mexico
7.5.3.1. Mexico Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.5.4. Argentina
7.5.4.1. Argentina Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.5.5. Rest of LATAM
7.5.5.1. Rest of LATAM Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6. MEA
7.6.1. MEA Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6.2. South Africa
7.6.2.1. South Africa Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6.3. South Arabia
7.6.3.1. South Africa Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6.4. UAE
7.6.4.1. UAE Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6.5. Kuwait
7.6.5.1. Kuwait Plasmid DNA Contract Manufacturing Market, 2021 - 2033
7.6.6. Rest of MEA
7.6.6.1. Rest of MEA Plasmid DNA Contract Manufacturing Market, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Plasmid DNA Contract Manufacturing Market: Company market share analysis, 2022 & 2030
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Charles River Laboratories
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. VGXI, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Plasmid Factory GmbH & Co. KG
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Boehringer Ingelheim Bioxellence
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. BioCina
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. ThermoFisher Scientific Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. VIVE Biotech
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. TriLink Biotechnologies
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Esco Aster Pte. Ltd
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers